How to Tell Biotech ’s Likely Winners From Losers

Merck ’s $10.8 billion acquisition of Prometheus Biosciences, which is developing a promising treatment for inflammatory bowel disease, is giving the entire biotech sector a lift. On Monday, the SPDR S&P Biotech ETF, which has underperformed other growth sectors this year, closed up 4.7%. For the…#merck #spdr #biotech #nasdaq100
Source: Reuters: Health - Category: Consumer Health News Source Type: news